Trials: Vaccines, Combined

Phase 4 N=653 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)

Hepatitis A Virus

Primary: Antibody Response to Hepatitis A - Participants With a Serological Response — 182; 158 Participants — p=<0.001

Merck Sharp & Dohme LLC Results Aug 2009 View details

Phase 4 N=1,271 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)

Hepatitis A Virus

Primary: Seropositivity Rate (SPR) to Hepatitis A — 100; 100; 100; 100 Percentage of participants

Merck Sharp & Dohme LLC Results Jul 2011 0.5% serious AE View details

Phase 4 N=1,800 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

Hepatitis A · Measles · Mumps

Primary: Participants With 1 or More Serious Vaccine-Related Adverse Experiences — 0; 1 participants

Merck Sharp & Dohme LLC Results Nov 2008 View details

Phase 4 N=1,341 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

Acellular Pertussis · Tetanus · Diphtheria

Primary: Number of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies — 427; 405; 425; 412 Participants

GlaxoSmithKline Results Mar 2017 0.2% serious AE View details

Phase 3 N=2,167 Safety and Immune Response of Different Pediatric Combination Vaccines.

Diphtheria · Polio · Pertussis

Primary: Percentage of Participant Responding to Pertussis Antigens Post-Dose 3 of Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Vaccinations. — 98; 99; 99; 99 Percentage of…

Sanofi Pasteur, a Sanofi Company Results Nov 2010 3.1% serious AE View details

Phase 3 N=5,803 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox

Varicella · Chickenpox Vaccines

Primary: Phase A: Number of Subjects With Confirmed Varicella Case — 37; 243; 201 Participants — p=<0.0001

GlaxoSmithKline Results Sep 2019 26.5% serious AE View details

Phase 3 N=452 Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants

Tetanus · Acellular Pertussis · Diphtheria

Primary: Number of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T) — 204; 211; 204; 211 Subjects

GlaxoSmithKline Results Oct 2018 7.1% serious AE View details

Phase 3 N=843 Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)

Neoplasms, Glandular and Epithelial · Diphtheria · Tetanus

Primary: Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 7 (4 Weeks Postdose 3) — 1151.3; 1244.9 milliMerck units/mL — p=<0.001

Merck Sharp & Dohme LLC Results Feb 2010 0.5% serious AE View details

Phase 3 N=473 ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

Herpes Zoster · Pneumococcal Infection

Primary: Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination — 448.5; 371.6 gpELISA units*/mL — p=0.244

Merck Sharp & Dohme LLC Results May 2009 View details

Phase 3 N=622 Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV

Hepatitis B · Polio · Diphtheria

Primary: Number of Participants With Seroprotection After Primary Series Vaccination With DTaP-IPV-Hep B-PRT~T or CombAct Hib™ + Engerix B™ + Oral Polio Vaccine (OPV) — 176; 185…

Sanofi Pasteur, a Sanofi Company Results May 2014 2.9% serious AE View details

Phase 3 N=1,042 Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)

Neoplasms, Glandular and Epithelial · Diphtheria · Tetanus

Primary: Number of Subjects Who Seroconverted for Human Papillomavirus (HPV) Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months) — 416; 417 Participants — p=<0.001

Merck Sharp & Dohme LLC Results Jul 2009 View details

Phase 3 N=2,133 Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants

Diphtheria · Tetanus · Pertussis

Primary: Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T…

Sanofi Pasteur, a Sanofi Company Results Oct 2013 2.0% serious AE View details

Phase 2 N=407 Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Haemophilus Influenzae Type b · Neisseria Meningitidis

Primary: Number of Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to 1 Milligram Per Milliliter — 72; 75; 65; 66 Subjects

GlaxoSmithKline Results Jul 2012 5.4% serious AE View details

Phase 3 N=955 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)

Varicella · Measles · Mumps

Primary: Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella — 97.4; 96.3; 96.7; 98.6 Percentage of Participants

Merck Sharp & Dohme LLC Results Mar 2018 1.8% serious AE View details

Phase 3 N=1,913 Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

Measles · Mumps · Rubella

Primary: Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥120 mIU/mL — 741; 383; 124 Participants

Merck Sharp & Dohme LLC Results Feb 2010 0.8% serious AE View details

Phase 3 N=1,027 V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Measles · Mumps · Rubella

Primary: Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥255 mIU/mL — 395; 203 Participants

Merck Sharp & Dohme LLC Results Feb 2010 0.4% serious AE View details

Phase 3 N=1,183 Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Meningitis, Meningococcal

Primary: Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W Antibodies Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With…

Sanofi Pasteur, a Sanofi Company Results Jun 2020 1.2% serious AE View details

Phase 3 N=379 Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine

Diphtheria · Tetanus · Pertussis

Primary: Number of Participants With Seroprotection to Hepatitis H Antigen After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV) or…

Sanofi Pasteur, a Sanofi Company Results Dec 2013 7.1% serious AE View details

Phase 3 N=735 Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)

Rotavirus Infections · Gastroenteritis

Primary: Geometric Mean Titer(s) of Poliovirus Types 1, 2, and 3, Measured Approximately 42 Days Postdose 3 — 888.0; 1139; 814.9; 814.5 Geometric Mean Titer (GMT) — p=<0.001

Merck Sharp & Dohme LLC Results Sep 2010 1.8% serious AE View details

Phase 3 N=552 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Meningococcal Disease · Meningococcal Meningitis · Typhoid

Primary: Geometric Mean Anti-typhoid Vi Antibody Concentrations — 6.37; 5.6; 134; 153 El.U/mL

Novartis Results Mar 2014 0.4% serious AE View details

Phase 3 N=2,133 Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.

Diphtheria · Tetanus · Pertussis

Primary: Number of Participants With High Fever Observed After Either DTaP-IPV-Hep B-PRP~T or Tritanrix Hep B/Hib™ + Placebo or Tritanrix-Hep B/Hib™ + Placebo Injection. — 56…

Sanofi Pasteur, a Sanofi Company Results Nov 2012 6.4% serious AE View details

Phase 3 N=1,072 Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years

Meningococcal Disease · Meningococcal Meningitis

Primary: Percentage of Subjects With an Immune Response Against Diphtheria, Tetanus and Pertussis, When Tdap is Concomitantly Administered With MenACWY-CRM Compared to Tdap Given…

Novartis Vaccines Results Jun 2014 0.3% serious AE View details

Phase 3 N=394 Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Hepatitis A

Primary: Number of Seropositive Subjects for Anti-hepatitis A Virus (HAV) Antibodies Following the Second Dose of Havrix — 88; 84; 77 Participants

GlaxoSmithKline Results Jul 2009 View details

Phase 3 N=1,796 Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Pneumococcal Disease

Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination With 20vPnC — 6.3; 7.4; 4.0; 3.3 Percentage of participants

Pfizer Results Jul 2022 3.7% serious AE View details

Phase 2 N=1,103 Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Neisseria Meningitidis · Haemophilus Influenzae Type b

Primary: Number of Subjects With Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Concentration Greater Than or Equal to 1.0 Microgram Per Milliliter (µg/mL) — 255; 76 Participants

GlaxoSmithKline Results Jul 2012 8.3% serious AE View details

Phase 2 N=1,551 ProQuad Dose Selection Study (V221-011)(COMPLETED)

Measles · Mumps · Rubella

Primary: Number of Participants With Varicella Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥ 5 gpELISA Units — 198; 299; 253; 303 Participants

Merck Sharp & Dohme LLC Results Feb 2010 0.4% serious AE View details

Phase 3 N=385 Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Neisseria Meningitidis · Bacterial Infections · Virus Diseases

Primary: Percentage of Participants With an Anti-Hepatitis B Surface Antigen (HBsAg) Antibody Titer ≥10 mIU/mL — 98.9 Percentage of Participants

MCM Vaccines B.V. Results Feb 2019 3.1% serious AE View details

Phase 3 N=1,473 Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Bacterial Infections · Virus Diseases

Primary: Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen — 84.97; 75.39; 97.25; 92.41 Percentage of participants — p=<0.001

Merck Sharp & Dohme LLC Results Mar 2016 6.2% serious AE View details

Phase 3 N=252 Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

Meningococcal Disease · Meningococcal Meningitis · Hepatitis A

Primary: Geometric Mean antiHAV and antiHBV Concentrations (GMCs), 28 Days After Primary and Booster Vaccination — 48; 30; 786; 884 Concentrations (mIU/mL)

Novartis Vaccines Results Mar 2014 0.8% serious AE View details

Phase 2 N=624 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants

Diphtheria · Tetanus · Pertussis

Primary: Percentage of Participants With Seroconversion for Anti-pertussis Toxoid and Anti-filamentous Hemagglutinin Antibodies Post-vaccination With Either DTaP-IPV-Hep B-PRP~T…

Sanofi Pasteur, a Sanofi Company Results Nov 2013 6.6% serious AE View details

Clinical Trial Search

Phase 4 N=653 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)

Phase 4 N=1,271 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)

Phase 4 N=1,800 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

Phase 4 N=1,341 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

Phase 3 N=2,167 Safety and Immune Response of Different Pediatric Combination Vaccines.

Phase 3 N=5,803 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox

Phase 3 N=452 Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants

Phase 3 N=843 Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)

Phase 3 N=473 ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

Phase 3 N=622 Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV

Phase 3 N=1,042 Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)

Phase 3 N=2,133 Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants

Phase 2 N=407 Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Phase 3 N=955 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)

Phase 3 N=1,913 Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

Phase 3 N=1,027 V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Phase 3 N=1,183 Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Phase 3 N=379 Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine

Phase 3 N=735 Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)

Phase 3 N=552 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Phase 3 N=2,133 Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.

Phase 3 N=1,072 Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years

Phase 3 N=394 Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Phase 3 N=1,796 Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Phase 2 N=1,103 Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Phase 2 N=1,551 ProQuad Dose Selection Study (V221-011)(COMPLETED)

Phase 3 N=385 Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Phase 3 N=1,473 Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Phase 3 N=252 Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

Phase 2 N=624 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants